Positive results were also reported for the cobimetinib plus vemurafenib treatment cohorts targeting BRAF mutations, including colorectal cancer with BRAF V600E mutations, with a DCR of 57%, median PFS duration of 15.8 weeks, and median OS duration of 38.9 weeks [64], and diverse tumors with BRAF V600E/D/K/R mutations, with a DCR of 68%, a median PFS duration of 5.8 months, and median OS duration of 15.2 months [65]. This evidence concerns the gene BRAF and colorectal cancer.